Upon joining Cambridge BioMarketing in 2013 as a group copy supervisor, Marissa McNally-Costello put her problem-solving skills to use. Quickly promoted to associate creative director, she led the marketing agency’s strategic and brand development for a number of global accounts, a role that included coming up with creative concepts and developing print, digital and experiential tactics.
In 2019, McNally-Costello was promoted to head of strategy, and again in 2020, this time to chief strategy officer. In her newest role, she manages the business with an eye to the future of the agency, and guides the medical, brand and omnichannel strategy teams.
McNally-Costello has been instrumental in a number of important drugs, notably Intercept Pharmaceutical’s Ocaliva, a semi-synthetic bile acid analog used for the treatment of primary biliary cholangitis. Due in large part to her leadership, Ocaliva’s launch remains one of the agency’s most-awarded campaigns.
Thanks to experience working across account management, creative and planning — as well as time spent on the client side — she is able to bring a 360-degree vision to product launches and commercial strategy. “Marissa has an incredible ability to really understand patients — especially rare disease patients, a cornerstone of Cambridge BioMarketing’s programs — and create messages that will resonate with them and make a meaningful impact,” said agency president Ben Beckley.
From the May 01, 2020 Issue of MM+M - Medical Marketing and Media
